JP2008519056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519056A5 JP2008519056A5 JP2007540134A JP2007540134A JP2008519056A5 JP 2008519056 A5 JP2008519056 A5 JP 2008519056A5 JP 2007540134 A JP2007540134 A JP 2007540134A JP 2007540134 A JP2007540134 A JP 2007540134A JP 2008519056 A5 JP2008519056 A5 JP 2008519056A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- salt
- compound
- patient
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 208000028017 Psychotic disease Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 230000036651 mood Effects 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000000810 Separation Anxiety Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 230000006978 adaptation Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 208000025874 separation anxiety disease Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62533504P | 2004-11-05 | 2004-11-05 | |
| PCT/US2005/040289 WO2006052886A1 (en) | 2004-11-05 | 2005-11-04 | Metabolites of certain [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008519056A JP2008519056A (ja) | 2008-06-05 |
| JP2008519056A5 true JP2008519056A5 (https=) | 2008-10-09 |
Family
ID=36002462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540134A Pending JP2008519056A (ja) | 2004-11-05 | 2005-11-04 | 特定の［１，４］ジアゼピノ［６，７，１−ｉｊ］キノリン誘導体の代謝物ならびにそれらの調製および使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20060111305A1 (https=) |
| EP (1) | EP1812436A1 (https=) |
| JP (1) | JP2008519056A (https=) |
| KR (1) | KR20070084009A (https=) |
| CN (1) | CN101124225A (https=) |
| AR (1) | AR052227A1 (https=) |
| AU (1) | AU2005304757A1 (https=) |
| BR (1) | BRPI0517100A (https=) |
| CA (1) | CA2586122A1 (https=) |
| CR (1) | CR9092A (https=) |
| GT (1) | GT200500319A (https=) |
| IL (1) | IL182755A0 (https=) |
| MX (1) | MX2007005475A (https=) |
| NO (1) | NO20072165L (https=) |
| PE (1) | PE20060939A1 (https=) |
| RU (1) | RU2007116264A (https=) |
| TW (1) | TW200635926A (https=) |
| WO (1) | WO2006052886A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500317A (es) * | 2004-11-05 | 2006-10-27 | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
| AR054849A1 (es) * | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
| TW200734334A (en) * | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
| KR20080110759A (ko) * | 2006-03-24 | 2008-12-19 | 와이어쓰 | 통증 치료 |
| CL2007000773A1 (es) * | 2006-03-24 | 2008-01-25 | Wyeth Corp | Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd. |
| KR20080105104A (ko) * | 2006-03-24 | 2008-12-03 | 와이어쓰 | 우울증 치료를 위한 신규한 치료학적 병용제 |
| CL2008002777A1 (es) * | 2007-09-21 | 2010-01-22 | Wyeth Corp | Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario. |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN111303218B (zh) * | 2020-03-17 | 2021-03-30 | 连江仁泽生物科技有限公司 | 一种马鞭草苷的合成方法及应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3158619A (en) * | 1962-06-14 | 1964-11-24 | Searle & Co | Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives |
| US3235564A (en) * | 1964-03-27 | 1966-02-15 | Searle & Co | Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives |
| US3335134A (en) * | 1964-04-02 | 1967-08-08 | Sandoz Ag | Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones |
| US3296252A (en) * | 1964-04-02 | 1967-01-03 | Sandoz Ag | Tetracyclic diazepinone compounds |
| GB1120461A (en) * | 1964-07-06 | 1968-07-17 | Manuf Prod Pharma | Derivatives of fluoreno-[1,9-ef]1,4-diazepine-1-oxide |
| US3417101A (en) * | 1964-11-09 | 1968-12-17 | American Home Prod | Fused ring compounds |
| US3329676A (en) * | 1964-11-09 | 1967-07-04 | American Home Prod | Fused 1, 4-diazepine ring systems |
| US3714149A (en) * | 1969-11-03 | 1973-01-30 | Upjohn Co | Pyridobenzodiazepinones |
| US3914250A (en) * | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
| US4880814A (en) * | 1987-11-13 | 1989-11-14 | Abbott Laboratories | 7-cycloalkyl naphthyridines |
| GB8812636D0 (en) * | 1988-05-27 | 1988-06-29 | Glaxo Group Ltd | Chemical compounds |
| US4997831A (en) * | 1988-09-01 | 1991-03-05 | Glaxo Group Limited | Lactam derivatives |
| CA2051697C (en) * | 1989-06-09 | 1996-10-08 | Malcolm Wilson Moon | Heterocyclic amines having central nervous system activity |
| NZ314105A (en) * | 1996-02-02 | 1997-12-19 | Sumitomo Pharma | Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring |
| US6380166B1 (en) * | 1999-09-13 | 2002-04-30 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols |
| US6761904B2 (en) * | 2000-03-31 | 2004-07-13 | Nycomed Austria Gmbh | Pharmaceutical kit comprising midodrine as active drug substance |
| AR031195A1 (es) * | 2000-11-03 | 2003-09-10 | Wyeth Corp | Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol |
| US6784172B2 (en) * | 2000-11-03 | 2004-08-31 | Wyeth | Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| US6777407B2 (en) * | 2000-11-03 | 2004-08-17 | Wyeth | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| US6414144B1 (en) * | 2000-11-03 | 2002-07-02 | Wyeth | Process for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi] indole derivatives |
| US7141563B2 (en) * | 2000-11-03 | 2006-11-28 | Wyeth | Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives |
| AR031201A1 (es) * | 2000-11-03 | 2003-09-10 | Wyeth Corp | /1,4/diazepino/6,7,1-jk/carbazoles y derivados |
| AR031199A1 (es) * | 2000-11-03 | 2003-09-10 | Wyeth Corp | Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados |
| US6759405B2 (en) * | 2000-11-03 | 2004-07-06 | Wyeth | Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| PL366233A1 (en) * | 2000-12-20 | 2005-01-24 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| CA2453219A1 (en) * | 2001-08-06 | 2003-02-20 | Pharmacia & Upjohn Company | Therapeutically useful tetracyclic ligands |
| TW200307540A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
| TWI312781B (en) * | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
| TW200307682A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| PL377426A1 (pl) * | 2002-12-19 | 2006-02-06 | Bristol-Myers Squibb Company | Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego |
| TW200734334A (en) * | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
| CL2007000773A1 (es) * | 2006-03-24 | 2008-01-25 | Wyeth Corp | Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd. |
-
2005
- 2005-11-03 AR ARP050104611A patent/AR052227A1/es unknown
- 2005-11-03 PE PE2005001292A patent/PE20060939A1/es not_active Application Discontinuation
- 2005-11-03 TW TW094138587A patent/TW200635926A/zh unknown
- 2005-11-04 EP EP05824172A patent/EP1812436A1/en not_active Withdrawn
- 2005-11-04 BR BRPI0517100-8A patent/BRPI0517100A/pt not_active IP Right Cessation
- 2005-11-04 CA CA002586122A patent/CA2586122A1/en not_active Abandoned
- 2005-11-04 JP JP2007540134A patent/JP2008519056A/ja active Pending
- 2005-11-04 GT GT200500319A patent/GT200500319A/es unknown
- 2005-11-04 CN CNA2005800449537A patent/CN101124225A/zh active Pending
- 2005-11-04 RU RU2007116264/04A patent/RU2007116264A/ru not_active Application Discontinuation
- 2005-11-04 MX MX2007005475A patent/MX2007005475A/es unknown
- 2005-11-04 WO PCT/US2005/040289 patent/WO2006052886A1/en not_active Ceased
- 2005-11-04 US US11/267,765 patent/US20060111305A1/en not_active Abandoned
- 2005-11-04 KR KR1020077010287A patent/KR20070084009A/ko not_active Withdrawn
- 2005-11-04 AU AU2005304757A patent/AU2005304757A1/en not_active Abandoned
-
2007
- 2007-04-23 IL IL182755A patent/IL182755A0/en unknown
- 2007-04-26 NO NO20072165A patent/NO20072165L/no not_active Application Discontinuation
- 2007-05-02 CR CR9092A patent/CR9092A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019031502A5 (https=) | ||
| JP2008534627A5 (https=) | ||
| TW200833685A (en) | Aminomethyl-4-imidazoles | |
| WO2007085556A3 (en) | Use of 4-imidazole derivatives for cns disorders | |
| JP2008524262A5 (https=) | ||
| JP2008044931A5 (https=) | ||
| JP2004534816A5 (https=) | ||
| EA200800946A1 (ru) | Антагонисты рецептора гистамина-3 | |
| WO2005079802A8 (en) | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | |
| ZA201005136B (en) | Substituted spirocyclic piperidine derivatives as histamine-3(h3)receptor ligands | |
| JP2002535408A5 (https=) | ||
| JP2008519056A5 (https=) | ||
| JP2012508275A5 (https=) | ||
| JP2003504303A5 (https=) | ||
| JP2015521642A5 (https=) | ||
| DOP2011000130A (es) | 1-(arilsulfonil)-4-(pepirazin-1-il)-1h-benzimidazol como ligando de 5-hidroxitriptamina-6 | |
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| JP2002525280A5 (https=) | ||
| JP2015521643A5 (https=) | ||
| WO2006019886A3 (en) | Pyrrolo(oxo)isoquinolines as 5ht ligands | |
| JP2008526706A5 (https=) | ||
| AR069904A1 (es) | Usos terapeuticos de compuestos con afinidad con el transportador de serotonina, los receptores de serotonina y el transportador de noradrenalina como por ejemplo, la 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sus sales terapeuticamente aceptables | |
| JP2007537293A5 (https=) | ||
| JPWO2020132474A5 (https=) |